New antidepressant drugs and the treatment of depression in the medically ill patient

Psychiatric Clinics of North America

Volumn 19, Issue 3, 1996, Pages 495-514

  Stoudemire, A ^a  

^a EMORY CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMFEPRAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CLOMIPRAMINE; CLONAZEPAM; CYTOCHROME P450; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; LORAZEPAM; NEFAZODONE; NEW DRUG; PAROXETINE; PHENOBARBITAL; PHENYTOIN; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; WARFARIN;

AKATHISIA; BLOOD PRESSURE; CLINICAL TRIAL; DEPRESSION; DRESSLER SYNDROME; DRUG MECHANISM; DRUG TRANSFORMATION; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HEART CONDUCTION; HUMAN; MEDICAL PRACTICE; NAUSEA; NERVOUSNESS; PHARMACODYNAMICS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; VOMITING;

EID: 0029840061     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0193-953X(05)70303-8     Document Type: Article

References (85)

1. I. Ahmed P.G. Dagincourt L.G. Miller Possible interaction between fluoxetine and pimozide causing sinus bradycardia Can J Psychiatry 38 1993 62 63
2. C.P. Alderman C.K. Moritz D.I. Ben-Tovim Abnormal platelet aggregation associated with fluoxetine therapy Ann Pharmacother 26 1992 1517 1519
3. B.B. Andersen M. Mikkelsen A. Vesterager No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin Epilepsy Res 10 1991 201 204
4. D.K. Arya E. Szabadi Dyskinesia associated with fluvoxamine [letter] J Clin Psychopharmacol 13 1993 365 366
5. R. Baldessarini E. Marsh Fluoxetine and side effects [letter] Arch Gen Psychiatry 47 1990 191 192
6. D. Baldwin N. Fineberg S. Montgomery Fluoxetine, fluvoxamine and extrapyramidal tract disorders Int Clin Psychopharmacol 6 1991 51 58
7. M.E. Bangs T.A. Petti M.D. Janus Fluoxetine-induced memory impairment in an adolescent J Am Acad Child Adolesc Psychiatry 33 1994 1303 1306
8. S.J. Bannister V.P. Houser J.D. Hulse Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin Acta Psychiatr Scand 80 suppl 350 1989 102 106
9. J. Barros G. Asnis An interaction of sertraline and desipramine [letter] Am J Psychiatry 150 1993 1751
10. K.E. Beliles A. Stoudemire Psychopharmacokinetics: Clinical applications in medical illnesses Stoudemire A. Fogel B.S. Medical-Psychiatric Practice vol 3 1995 American Psychiatric Press Washington DC 1 77
11. P. Benfield A. Ward Fluvoxamine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness Drugs 32 1986 313 334
12. R.F. Bergstrom C.M. Beasley N.B. Levy The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetine Int Clin Psychopharmacol 8 1993 261 266
13. R.F. Bergstrom A.L. Peyton L. Lemberger Quantification and mechanism of fluoxetine and tricyclic antidepressant interaction Clin Pharmacol Ther 51 1992 239 248
14. G. Bertschy S. Vandel B. Bandel Fluvoxamine-tricyclic antidepressant interaction Eur J Clin Pharmacol 40 1991 119 120
15. C.F. Caley J.H. Friedman Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiatry 53 1992 278 282
16. N.E. Caporaso G.L. Shaw Clinical implications of the competitive inhibition of the debrisoquin-metabolizing isozyme by quinidine Arch Intern Med 151 1991 1985 1992
17. F. Centorrino R.J. Baldessarini J. Kando Serum concentrations of clozapine and its major metabolites: Effects of cotreatment with fluoxetine or valproate Am J Psychiatry 151 1994 123 125
18. D.A. Ciraulo R.I. Shader Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics J Clin Psychopharmacol 10 1990 48 50
19. W.G. Clark D.C. Brater A.R. Johnson Goth's Medical Pharmacology ed 13 1992 Mosby–Year Book St Louis 260
20. H.K. Crewe M.S. Lennard G.T. Tucker The effect of selective serotonin re-uptake inhibitors on chyochrome P4502D6 (CYP2D6) activity in human liver microsomes Br J Clin Pharmacol 34 1992 262 265
21. K. Dalhoff T.P. Almdal K. Bjerrum Pharmacokinetics of paroxetine in patients with cirrhosis Eur J Clin Pharmacol 41 1991 351 354
22. M. Dave Fluoxetine-associated dystonia [letter] Am J Psychiatry 151 1994 149
23. J. Davidson Seizures and bupropion: A review J Clin Psychiatry 50 1989 256 261
24. K.L. Dechant S.P. Clissold Paroxetine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness Drugs 41 1991 225 253
25. C.L. DeVane Pharmacokinetics of the newer antidepressants: Clinical relevance Am J Med 97 suppl 6A 1994 13S 23S
26. A.E. Epstein A.P. Hallstrom W.J. Rogers Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction JAMA 270 1993 2451 2455
27. C. Fisch S.B. Knoebel Electrocardiographic findings in sertraline depression trials Drug Invest 4 1992 305 312
28. J. Fritze B. Unsorg M. Lanczik Interaction between carbamazepine and fluvoxamine Acta Psychiatr Scand 84 1991 538 584
29. Gelenberg A.J. Bassuk E.L. Schoonover S.C. The Practitioners Guide to Psychoactive Drugs ed 3 1991 Plenum New York 43
30. M. Gibaldi Drug interactions: I. Inhibition of Drug Metabolism Ann Pharmacother 26 1992 709 713
31. B.E. Gidal G.D. Aderson T.L. Seaton Evaluation of the effect of fluoxetine on the formation of carbamazepine epoxide Ther Drug Monit 15 1993 405 409
32. A.H. Glassman S.P. Roose J.T. Bigger The safety of tricyclic antidepressants in cardiac patients: Risk-benefit reconsidered JAMA 269 1993 2673 2675
33. D.C. Goff K.K. Midha A.W. Brotman Elevation of plasma concentrations of haloperidol after the addition of fluoxetine Am J Psychiatry 148 1991 790 792
34. W.H. Greb G. Buscher H.-D. Dierdorf Effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine Acta Psychiatr Scand 80 suppl 350 1989 95 98
35. D.J. Greenblatt D.R. Abernethy A. Locniskar Age, sex, and nitrazepam kinetics: Relation to antipyrine disposition Clin Pharmacol Ther 38 1985 697 703
36. D.J. Greenblatt S.H. Preskorn M.M. Cotreau Fluoxetine impairs clearance of alprazolam but not of clonazepam Clin Pharmacol Ther 52 1992 479 486
37. S.R. Grimsley M.W. Jann J.G. Carter Increased carbamazepine plasma concentrations after fluoxetine coadministration Clin Pharmacol Ther 50 1991 10 15
38. S. Hansen-Grant K.R. Silk S. Guthrie Fluoxetine-pimozide interaction [letter] Am J Psychiatry 150 1993 1751 1752
39. R. Jochemsen B.R. vanBeusekom P. Spoelstra Effect of age and liver cirrhosis on the pharmacokinetics of nitrazepam Br J Clin Pharmacol 15 1983 295 302
40. L.K. Laird R.B. Lydiard W.A. Morton Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients J Clin Psychiatry 54 1993 224 228
41. T.A. Lasher J.C. Fleishaker R.C. Steenwyk E.J. Antal Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine Psychopharmacology 104 1991 323 327
42. L. Lemberger H. Rowe J.C. Bosomworth The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam Clin Pharmacol Ther 43 1988 412 419
43. A. Lemoine J.C. Gautier D. Azoulay Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver Mol Pharmacol 43 1993 827 832
44. J.D. Lock H.E. Gwirtsman E.F. Targ Possible adverse drug interactions between fluoxetine and other psychotropics J Clin Psychopharmacol 10 1990 383 384
45. P. Malek-Ahmadi S.A. Allen Paroxetine-Molindone interaction J Clin Psychiatry 56 1995 82 83
46. L.J. McKenzie S.C. Risch Fibrocystic breast disease following treatment with selective serotonin reuptake inhibitors [letter] Am J Psychiatry 152 1995 471
47. Medical Letter Fluvoxamine for obsessive-compulsive disorder The Medical Letter 37 942 1995 13 14
48. F.S. Messiha Fluoxetine: Adverse effects and drug-drug interactions Clin Toxicology 31 1993 603 630
49. J. Morganroth J.E. Goin Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias: A meta-analysis Circulation 84 1991 1977 1983
50. S.D. Nicholson Extra pyramidal side effects associated with paroxetine West of England Medical Journal 7 1992 90 91
51. S. Ohmori S. Takeda T. Rikihisa Studies on cytochrome P450 responsible for oxidative metaolism of imipramine in human liver microsomes Biol Pharm Bull 16 1993 571 575
52. E. Perucca G. Gatti E. Spina Clinical pharmacokinetics of fluvoxamine Clinical Pharmacokinet 27 1994 175 190
53. Physicians' Desk Reference ed 48 1994 Medical Economics Data Production Co. Montvale NJ 762 765
54. S.H. Preskorn J. Alderman M. Chung Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine J Clin Psychopharmacol 14 1994 90 98
55. S.H. Preskorn M. Burke Somatic therapy for major depressive disorder: Selection of an antidepressant J Clin Psychiatry 53 1992 5 18
56. E. Richelson Treatment of acute depression Psychiatr Clin North Am 16 1993 461 478
57. S.P. Roose G.W. Dalack A.H. Glassman Cardiovascular effects of bupropion in depressed patients with heart disease Am J Psychiatry 148 1991 512 516
58. S.P. Roose A.H. Glassman E.G.V. Giardina Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure J Clin Psychopharmacol 7 1987 247 251
59. H. Rowe R. Carmichael L. Lemberger The effect of fluoxetine on warfarin metabolism in the rat and man Life Sci 23 1978 807 812
60. E. Schweizer J. Feighner L.A. Mandos Commparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients J Clin Psychiatry 55 1994 104 108
61. R. Sovner J.M. Davis A potential drug interaction between fluoxetine and valproic acid [letter] J Clin Psychopharmacol 11 1991 389
62. A.D. Sperber Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy Drug Safety 6 1991 460 462
63. E. Spina A. Avenoso A.M. Pollicino Carbamazepine coadministration with fluoxetine or fluvoxamine Therapeutic Drug Monitoring 15 1993 247 250
64. E. Spina A.M. Pollicino A. Avenoso Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects Ther Drug Monit 15 1993 243 246
65. E. Spina A.M. Pollicino A. Avenoso Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients Int J Clin Pharmacol Res 13 1993 167 171
66. E.N.H.J. Steur Increase of Parkinson disability after fluoxetine medication Neurology 43 1993 211 213
67. A. Stoudemire B.S. Fogel Psychopharmacology in medical patients: An Update Stoudemire A. Fogel B.S. Medical-Psychiatric Practice vol 3 1995 American Psychiatric Press Washington, DC 79 149
68. A. Stoudemire B.S. Fogel L.R. Gulley Psychopharmacology in the medical patient Stoudemire A. Fogel B.S. Psychiatric Care of the Medical Patient 1993 Oxford University Press New York 155 206
69. Strouse TB, Skotzko CE, Fawzy FI: Absence of adverse drug interactions between fluoxetine & cyclosporine in organ transplant recipients. Presented at the Annual Meeting of the Academy of Psychosomatic Medicine. New Orleans, November 1993
70. M.P. Swims Potential terfenadine-fluoxetine interaction [letter] Ann Pharmacother 27 1993 1404 1405
71. J.L. Tate Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine Am J Psychiatry 146 1989 399 400
72. K.K. Teo S. Yusuf C.D. Furberg Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction JAMA 270 1993 1589 1595
73. S. Troy A. Piergies I. Lucki Venlafaxine pharmacokinetics and pharmacodynamics [abstract] Clin Neuropharmacol 15 suppl 1B 1992 324B
74. J. van Harten J. Duchier J. Devissaguet Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration Clin Pharmacokinet 24 1993 177 182
75. J. van Harten R.L. Holland K. Wesnes Influence of multiple-dose administration of fluvoxamine on the pharmacokinetics of the benzodiazepines bromazepam and lorazepam: A randomised, cross-over study [abstract] European Neuropsychopharmacol 2 1992 381
76. van Harten J, Holland RL, Wesnes K, et al: Kinetic and dynamic interaction study between fluvoxamine and benzodiazepines. Poster presented at the Second Jerusalem Conference on Pharmaceutical Sciences and Clinical Pharmacology. Jerusalem, Israel, May 24–29, 1992
77. J. van Harten L.A. Stevens M. Raghoebar Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function Clin Pharmacol Ther 52 1992 427 435
78. L.L. von Moltke D.J. Greenblatt J.S. Harmatz Cytochromes in psychopharmacology [editorial] J Clin Psychopharmacol 14 1994 1 4
79. T. Walley M. Pirmohamed C. Proudlove Interaction of metoprolol and fluoxetine [letter] Lancet 341 1993 967 968
80. S.J. Warrington Clinical implications of the pharmacology of sertraline Int Clin Psychopharmacol 6 suppl 2 1991 11 21
81. S.J. Warrington Y. Lewis Cardiovascular effects of antidepressants: Studies of paroxetine in healthy men and depressed patients Int Clin Psychopharmacol 6 suppl 4 1992 59 64
82. K.D. Wilner J.D. Lazar G. Apseloff The effects of sertraline on the pharmacodynamics of warfarin in healthy volunteers [abstract] Biol Psychiatry 29 1991 354S 355S
83. V. Wils Extrapyramidal symptoms in a patient treated with fluvoxamine [letter] J Neurol Neurosurg Psychiatry 55 1992 330 331
84. D.J. Woods D.M. Coulter P. Pillans Interaction of phenytoin and fluoxetine [letter] N Z Med J 107 1994 19
85. Wyeth Laboratories: Effexor (venlafaxine) package insert, Philadelphia, PA, December, 1993